Cambridge Healthtech Institute’s 3^rd Annual

Bispecific Antibody Design

Advances in Engineering Bi- and Multi-Specific Platforms

August 25-26, 2020

Bispecific antibodies continue to show significant and impressive therapeutic value with many successes, including more than 100 different formats, and about 80 bispecific antibodies are currently in clinical trials. While the development of bispecific antibodies is an evolving field, many challenges are still waiting to be solved by experts in the field, including target selection, combination strategies, better understanding of their mechanism of action for rational design, along with reducing off-target toxicity and cytokine release syndromes. CHI’s Third Annual Bispecific Antibody Design conference will delve directly into the technical challenges of bispecific development to improve your candidates’ translatability into the clinic.

Preliminary Agenda

Current Landscape and Outlook of Bispecific Antibody

Roland Kontermann, PhD, Professor, Biomedical Engineering, Institute of Cell Biology and Immunology, University of Stuttgart

LockBody - Safe and Selective Engagement of Anti-Cancer Mechanisms in Solid Tumors

Jamie Coleman, PhD, COO, UltraHuman Ltd.

Revision of RTK Tumor Targeting: How to Design Truly Potent Bispecific and Biparatopic Agents

Rastislav Tamaskovic, PhD, Head, TC Facility, Biochemistry, University of Zurich

RSL-DVDs: An Improved Disulfide-Reinforced Single Linker DVD-Ig Bispecific Format

Charles Cheung, PhD, Principal Research Scientist, Global Biologics, Abbvie

Optimal PD-L1 x CD137 Bispecific Molecules for Tumor Immune Activation

Gundo Diedrich, PhD, Senior Director, Antibody Engineering, MacroGenics

T Cell Engagers which Apply the DARPin® Technology for Selective Targeting of Tumor-Associated MHC Class I/Peptide Complexes

Marcel Walser, PhD, Director, Molecular Partners AG

COBRA – A New Class of Conditionally Active, T Cell Engaging Bispecifics for the Treatment of Solid Tumors

Patricia Culp, PhD, Senior Director, Cell Biology & Assay Development, Maverick Therapeutics

Triclonics™ Engagers: Using a Tri-specific Common Light Chain Antibody Platform and Unbiased Functional Screening to Discover the Next Generation of T Cell Engagers

Simon Plyte, PhD, VP, Immuno-Oncology, Merus

BEAT® 2.0 – Ichnos’ Next-Generation Bi- and Multispecific Antibody Platform

Stanislas Blein, PhD, Vice President, Antibody Engineering, Discovery, Ichnos Sciences SA

For more details on the conference, please contact:
Emily Le

Conference Producer

Cambridge Healthtech Institute

Phone: 781-247-1812
Email: ele@healthtech.com

For partnering and sponsorship information, please contact:

Companies A-K

Jason Gerardi

Senior Manager, Business Development

Cambridge Healthtech Institute